Inhibikase Therapeutics, Inc. Stock Analysis & AI Score
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Inhibikase Therapeutics, Inc. (IKT) holds an ST Score of 65.8 out of 100 (B), with its strongest factor being Financial Strength (A+) and its weakest Growth (C). IKT last traded at $2.30.
- Strongest
- Financial StrengthA+
- Weakest
- GrowthC
All factor grades
- Financial StrengthA+
- ValuationA
- ForecastA
- MomentumA-
- ProfitabilityB-
- GrowthC
- Piotroski2/9
Contact
IKT stock: frequently asked questions
What is IKT's ST Score?
Inhibikase Therapeutics, Inc. (IKT) has an ST Score of 65.8 out of 100, an overall grade of B. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is IKT a buy, sell, or hold?
Our own ST Score grades it B (65.8/100). This is data, not investment advice — always do your own research.
What is IKT's valuation grade?
Inhibikase Therapeutics, Inc. (IKT) earns a valuation grade of A, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is IKT's growth grade?
Inhibikase Therapeutics, Inc. (IKT) earns a growth grade of C, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is IKT's profitability grade?
Inhibikase Therapeutics, Inc. (IKT) earns a profitability grade of B-, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is IKT's financial strength grade?
Inhibikase Therapeutics, Inc. (IKT) earns a financial strength grade of A+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is IKT's Piotroski score?
Inhibikase Therapeutics, Inc. (IKT) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.